Standard Biotools (LAB) Cash & Current Investments (2010 - 2026)

Standard Biotools (LAB) has 17 years of Cash & Current Investments data on file, last reported at $455.2 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 74.63% year-over-year to $455.2 million in Q1 2026; TTM through Mar 2026 was $455.2 million, a 74.63% increase from a year earlier, with the FY2025 full-year figure at $187.6 million, down 36.41% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $455.2 million, up from $187.6 million in the prior quarter.
• Over the last five years, Cash & Current Investments for LAB reached as high as $463.6 million in Q1 2024 and fell as low as $31.0 million in Q1 2022.
• Historically, Cash & Current Investments has averaged $235.1 million across 5 years, with a median of $194.9 million in 2025.
• Across the five-year window, Cash & Current Investments surged 20788.48% in 2022 and tumbled 46.98% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $166.8 million in 2022, then tumbled by 30.64% to $115.7 million in 2023, then surged by 154.96% to $295.0 million in 2024, then slumped by 36.41% to $187.6 million in 2025, then jumped by 142.66% to $455.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $455.2 million in Q1 2026, $187.6 million in Q4 2025, and $194.9 million in Q3 2025.